I recently returned from Brazil where I participated in a cancer symposium.
During my visit I encountered many highly skilled physicians with expertise in breast, thoracic, gastrointestinal and orthopedic oncology.
The degree of collegiality and enthusiasm was palpable.
The most exciting aspect of my visit was the warm reception and extremely high level of interest in the clinical application of our laboratory platform. It was a refreshing reminder that the parochial thinking of the American oncology community is not the norm throughout the world.
Ovarian Cancer Treatment Success from India
Upon my return, I had the pleasure of meeting a charming 61-year-old woman from New Delhi, India. In review of her chart I recognized her name as a patient for whom we had conducted a study in February of 2012.
Her husband, an accomplished businessman, had learned of our laboratory and worked diligently to obtain, process and transport a portion of his wife's tumor from the surgical suite to our lab.
Despite multiple recurrent disease and numerous prior treatments, this patient's Stage 4 ovarian cancer cells revealed exquisite sensitivity to a drug combination in the laboratory.
Her physicians at the Apollo Hospital of New Delhi delivered the treatment exactly as outlined by our lab, and here sitting across from me was the patient in complete remission six months later. The family had traveled from India to meet me and express their thanks.
The Globalization of Cancer Care
Each of these experiences speaks volumes for the globalization of cancer care.
Cancer patients, whether from Brazil, India or China are more alike than different. Each confronts a seemingly insurmountable adversary.
Each in their own way seeks out the best information and advice.
And each can be best managed with those treatments found uniquely effective for their tumor.
Perhaps once we have conquered cancer in India and Brazil, the EVA-PCD® assay will be ultimately more widely accepted in the United States of America.